Senior Scientist, Clinical Epidemiology Program
Ottawa Hospital Research Institute
Director, Clinical Epidemiology Program
Ottawa Hospital Research Institute
Full Professor, Departments of Medicine, Surgery, & of Epidemiology and Community Medicine
University of Ottawa
Endowed Chair, Clinical Epidemiology Program
Ottawa Hospital Research Institute/University of Ottawa
I have focused my research contributions in two major areas:
1) transfusions and transfusion alternatives
2) methodological research into the ethics, design and analysis of clinical trials.
Dr. Fergusson is a Senior Scientist & Director, Clinical Epidemiology Program, at the Ottawa Hospital Research Institute. He is also a Full Professor, Departments of Medicine, Surgery, & of Epidemiology and Community Medicine, University of Ottawa. Dr. Fergusson holds the position of Endowed Chair, OHRI/uOttawa, Clinical Epidemiology Program.
He holds a PhD (Honours) in Epidemiology and Biostatistics from McGill University and a Masters of Health Administration from the University of Ottawa. Dr. Fergusson’s clinical research interests are mainly in the field of transfusion medicine with a focus on transfusion alternatives and the effectiveness of blood products. His research interests also extend to the methodology and ethics of clinical trials and systematic reviews. Dr. Fergusson is a principal investigator on a number of large, peer-reviewed clinical trials in transfusion medicine including “Blood Conservation Using Antifibrinolytics: Randomized Trial in High-Risk Cardiac Surgery (BART)”, Age of Red Blood Cells in Premature Infants (ARIPI), “Age of Blood Evaluation (ABLE)”. Dr. Fergusson has contributed over 350 articles, abstracts, and book chapters to the medical literature.
- Lacroix J, Hébert PC, Fergusson DA, Tinmouth A, Cook DJ, Marshall JC, Clayton L, McIntyre L, Callum
J, Turgeon AF, Blajchman MA, Walsh TS, Stanworth SJ, Campbell H, Capellier G, Tiberghien P,
Bardiaux L, van de Watering L, van der Meer NJ, Sabri E, Vo D; ABLE Investigators and the Canadian
Critical Care Trials Group.(2015). Age of Transfused Blood in Critically Ill Adults. N Engl J Med.372(15):
- Seely A, Bravi A, Herry C, Green G, Longtin A, Ramsay T, Fergusson D, McIntyre L, Kubelik D, Maziak
DE, Ferguson N, Brown SM, Mehta S, Martin C, Rubenfeld G, Jacono FJ, Clifford G, Fazekas A,
Marshall J; Canadian Critical Care Trials Group (CCCTG); Canadian Critical Care Trials Group CCCTG.
(2014). Erratum to: Do heart and respiratory rate variability improve prediction of extubation outcomes in
critically ill patients?. Crit Care.18(6): 620.
- Zarychanski R , Abou-Setta AM , Turgeon AF , Houston BL , McIntyre L , Marshall JC , Fergusson
DA. (2013). Association of hydroxyethyl starch administration with mortality and acute kidney injury in
critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA. 309(7): 678-88.
- Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussières JS, Côté D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R; BART Investigators.(2008). A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. The New England journal of medicine. 358(22): 2319-31.
- Fergusson D, Khanna MP, Tinmouth A, Hébert PC.(2004). Transfusion of leukoreduced red blood
cells may decrease postoperative infections: two meta-analyses of randomized controlled trials.Can J